A Phase 3 interventional study of MP-424 (generic name:Telaprevir) and Ribavirin in Chronic Hepatitis C, sponsored by Tanabe Pharma Corporation. Completed at 1 site in Japan. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-06.
Sponsored by Tanabe Pharma Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing telaprevir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. telaprevir · Hepatitis C, Chronic.
Among the 27 studies testing telaprevir in Hepatitis C, Chronic, this one is the 23rd largest by enrollment, is one of 4 that started in 2011, is one of 12 in phase 3, and was the 13th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 27 studies testing telaprevir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
telaprevir: first FDA approval 2011 (INCIVEK), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 20 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 54 across the 27 interventional studies. Of the 25 that completed or were terminated, 16 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 27 have an industry lead sponsor. The 10 most frequent:
Tanabe Pharma Corporation is the lead sponsor of 92 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
11 studies in Hepatitis C, Chronic by Tanabe Pharma Corporation: none open now, none under way, none of them phase 3. Of 11 finished, 10 (91%) have results posted.
Among the 11 studies in Hepatitis C, Chronic by Tanabe Pharma Corporation, this one is the 10th largest by enrollment, is the only one that started in 2011, is one of 7 in phase 3, and was the 7th registered.
Tanabe Pharma Corporation’s Hepatitis C, Chronic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 27 studies testing telaprevir in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Tanabe Pharma Corporation’s 11 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and Ribavirin (RBV) in patients with genotype 2 hepatitis C, who did not respond to previous treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MP-424 (generic name:Telaprevir) · Drug: Ribavirin · Drug: Peginterferon alfa-2b
750mg q8h for 12 weeks
400 - 1000 mg/day based on body weight for 24 weeks
1.5mcg/kg/week for 24 weeks
Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)
Time frame: After 24 weeks of follow-up
| Milestone | MP-424 |
|---|---|
| Started | 10 |
| Completed | 10 |
| Not completed | 0 |
| percentage of subjects achieving SVR | MP-424 |
|---|---|
| Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response) | 50.0 (18.7 to 81.3) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MP-424 | — | 0/10 (0%) | 10/10 (100%) |
| Event | MP-424 |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 7/10 |
| Injection site reactionGeneral disorders | 6/10 |
| Blood bilirubin increasedInvestigations | 5/10 |
| Decreased appetiteMetabolism and nutrition disorders | 4/10 |
| MalaiseGeneral disorders | 4/10 |
| PyrexiaGeneral disorders | 4/10 |
| Blood uric acid increasedInvestigations | 4/10 |
| Platelet count decreasedInvestigations | 4/10 |
| NasopharyngitisInfections and infestations | 3/10 |
| HeadacheNervous system disorders | 3/10 |
| Age, Continuous(years) | MP-424 |
|---|---|
| Mean | 56.8 ± 6.7 |
| Sex: Female, Male(Participants) | MP-424 |
|---|---|
| Female | 2 |
| Male | 8 |
The record gives a start of Nov 2011, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2014, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Telaprevir · Ribavirin · Peginterferon alfa-2b